Imricor Q3 revenue surges 437% to US$188,000
Key points
- Imricor reported Q3 2026 revenue of US$188,000, marking a 437% increase over the prior corresponding period.
- The company ended the quarter with US$62.1 million in cash and cash equivalents.
- Management initiated its U.S. commercial launch, securing two paediatric hospital customers and launching a new cardiovascular business vertical.
Imricor Medical Systems (ASX:IMR) recorded a 437% revenue increase to US$188,000 for Q3 2026 as US sales began.
This growth contrasts with the prior corresponding period and reflects initial U.S. installations following recent regulatory clearances.
Revenue from the second U.S. customer, Children's Medical Centre Dallas, will be recognised in Q4 following post-quarter installation.
The company holds US$62.1 million in cash and reported 14 of 15 FDA submissions complete or under review.
Following the announcement, the Imricor Medical Systems share price was up at $1.33.
Imricor develops MR-compatible medical devices designed to enable radiation-free cardiac catheterisation procedures under real-time magnetic resonance guidance.
Recent milestones include launching Imricor Finance with DLL, securing Philips scanner compatibility, and completing paediatric label expansions for NorthStar.
Frequently asked questions
More from Australia
Accent Group reports 3.9% drop in FY27 retail sales
BHP restructures Australian iron ore unit after cutting 300 jobs
Clarity Pharmaceuticals wins FDA breakthrough designation for 64Cu-SAR-bisPSMA
Arika Resources begins 3,000-metre drilling at Pennyweight Point
Core Energy Minerals starts 2,650m uranium drilling in Namibia
COSOL signs $11M US transit contract
